Diagnostics firm Indi snags $47.3M for lung tests

Seattle startup Integrated Diagnostics, or Indi, picked up $47.3 million in equity and debt financing, money it'll use to expand the market for its lung nodule-diagnosing test. Under the financing deal, Indi raised $30.3 million in Series B money from investors including Baird Capital, InterWest Partners and the Wellcome Trust, and separately secured a $17 million debt facility from Life Sciences Alternative Funding. Now, the company is planning to amp up marketing for its Xpresys test, designed to cheaply determine whether lung growths are benign, ruling out costlier biopsies and saving money for patients and providers. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.